分享:
分享到微信朋友圈
X
• 临床研究 •
APT成像联合T2-FLAIR在无对比剂强化弥漫性胶质瘤中的应用价值
王凌飞 陈龙华 卢禹 贾鹏 张武 岳毅明 李雯

本文引用格式 王凌飞, 陈龙华, 卢禹, 等. APT成像联合T2-FLAIR在无对比剂强化弥漫性胶质瘤中的应用价值[J]. 磁共振成像, 2026, 17(11): 70-77. DOI:10.12015/issn.1674-8034.2026.11.009.


[摘要] 目的 探讨酰胺质子转移成像(amide proton transfer imaging, APT)联合T2液体衰减反转恢复(T2 fluid-attenuated inversion recovery, T2-FLAIR)序列在无对比剂强化弥漫性胶质瘤分级诊断、异柠檬酸脱氢酶(isocitrate dehydrogenase, IDH)基因分型预测中的临床应用价值,为该类病变的精准诊疗提供无创影像学依据。材料与方法 回顾性随机纳入2021年1月至2025年3月本院经手术病理证实的120例无强化弥漫性胶质瘤患者,所有患者术前均完成了3.0 T MRI的APT及T2-FLAIR序列扫描。根据世界卫生组织(World Health Organization, WHO)分级将患者分为低级别组(WHO 2级,n=56)和高级别组(WHO 3~4级,n=64);根据术后病理 IDH 基因检测结果分为突变型组(n=72)和野生型组(n=48)。然后由2名资深影像医师双盲法分析图像,测量并计算APT值、T2-FLAIR相对信号强度(relative signal intensity, rSI),判断T2-FLAIR mismatch征,采用组内相关系数(intra-class correlation coefficient, ICC)检验观察者间一致性;通过独立样本t检验、χ2检验比较不同分级、不同IDH基因型患者的影像学指标差异,绘制受试者工作特征(receiver operating characteristic curve, ROC)曲线评估各指标及联合指标的诊断效能。结果 2名医师测量的 APT值、T2-FLAIR rSI及肿瘤最大径ICC分别为0.89、0.92、0.90,一致性良好;高级别组APT值、T2-FLAIR rSI及肿瘤最大径均高于低级别组(t值分别为18.723、15.689、19.871,P<0.001),IDH 野生型组APT值高于突变型组(t=17.652,P<0.001);T2-FLAIR mismatch征阳性率低于突变型组(χ2=28.741,P<0.001);APT值联合T2-FLAIR rSI诊断高级别胶质瘤的曲线下面积(area under the curve, AUC)为0.942,95% CI:0.891~0.974,敏感度90.63%,特异度87.50%,截断值2.71,高于单一指标;APT值联合T2-FLAIR mismatch征预测IDH野生型胶质瘤的AUC为0.915,95% CI:0.856~0.953,敏感度85.42%,特异度88.89%,截断值2.68,高于单一指标。结论 APT 联合T2-FLAIR序列可从分子代谢与形态学双维度实现优势互补,能提高无强化弥漫性胶质瘤分级诊断的准确性及IDH基因分型的预测效能,可为临床制订个体化治疗方案提供可靠的无创影像学依据。
[Abstract] Objective To investigate the clinical value of amide proton transfer (APT) imaging combined with T2 fluid-attenuated inversion recovery (T2-FLAIR) sequence in grading diagnosis and prediction of isocitrate dehydrogenase (IDH) genotyping of non-enhancing diffuse gliomas, so as to provide non-invasive imaging evidence for precise diagnosis and treatment of such lesions.Materials and Methods A total of 120 patients with pathologically confirmed non-enhancing diffuse gliomas in our hospital from January 2021 to March 2025 were retrospectively enrolled. All patients underwent preoperative 3.0 T MRI examinations including APT and T2-FLAIR sequences. According to the World Health Organization (WHO) classification criteria, patients were divided into low-grade group (WHO grade 2, n = 56) and high-grade group (WHO grade 3-4, n = 64). Based on postoperative pathological IDH genotyping results, patients were classified into IDH-mutant group (n = 72) and IDH-wild-type group (n = 48). Two senior radiologists performed double-blinded image analysis. The APT value and relative signal intensity (rSI) of T2-FLAIR were measured and calculated, and the T2-FLAIR mismatch sign was assessed. Intra-class correlation coefficient (ICC) was used to evaluate inter-observer agreement. Independent-samples t-test and χ2-test were adopted to compare imaging parameters among groups with different pathological grades and IDH genotypes. Receiver operating characteristic (ROC) curves were plotted to assess the diagnostic efficacy of single and combined imaging parameters.Results The intraclass correlation coefficient (ICC) values for APT value, T2 fluid-attenuated inversion recovery (T2-FLAIR) relative signal intensity (rSI), and maximum tumor diameter measured by two radiologists were 0.89, 0.92, and 0.90, respectively, indicating excellent inter-observer consistency. The APT value, T2-FLAIR rSI, and maximum tumor diameter were significantly higher in the high-grade glioma group than in the low-grade group (t = 18.723, 15.689, and 19.871, all P < 0.001). The APT value was significantly higher in the isocitrate dehydrogenase (IDH) wild-type group than in the IDH-mutant group (t = 17.652, P < 0.001), while the positive rate of the T2-FLAIR mismatch sign was significantly lower in the wild-type group (χ2 = 28.741, P < 0.001). The combination of APT value and T2-FLAIR rSI yielded an area under the curve (AUC) of 0.942 (95% CI: 0.891 to 0.974) for diagnosing high-grade glioma, with a sensitivity of 90.63%, a specificity of 87.50%, and a cut-off value of 2.71, which was significantly superior to that of each single parameter. Furthermore, the combined model of APT value and T2-FLAIR mismatch sign achieved an AUC of 0.915 (95% CI: 0.856 to 0.953) for predicting IDH wild-type glioma, with a sensitivity of 85.42%, a specificity of 88.89%, and a cut-off value of 2.68, showing better diagnostic performance than individual indicators.Conclusions The combination of APT imaging and T2-FLAIR sequence integrates molecular metabolic and morphological information with complementary advantages. It can significantly improve the accuracy of grading diagnosis and the predictive performance of IDH genotyping for non-enhancing diffuse gliomas, and provide reliable non-invasive imaging evidence for individualized clinical treatment strategies.
[关键词] 胶质瘤,弥漫性;磁共振成像;酰胺质子转移成像;T2液体衰减反转恢复序列;分级诊断;异柠檬酸脱氢酶基因分型
[Keywords] glioma, diffuse;magnetic resonance imaging;amide proton transfer imaging;T2 fluid-attenuated inversion recovery sequence;grading diagnosis;isocitrate dehydrogenase genotyping

王凌飞    陈龙华    卢禹 *   贾鹏    张武    岳毅明    李雯   

南阳医学高等专科学校第一附属医院磁共振科,南阳 473000

通信作者:卢禹,E-mail: wangef20000@163.com

作者贡献声明:卢禹、陈龙华设计本研究的方案,对稿件的重要内容进行了修改,陈龙华获得了河南省科技发展计划项目的资助,卢禹获得了南阳市科技发展计划项目的资助;王凌飞起草和撰写稿件,获取、分析和解释本研究的数据;张武、李雯、岳毅明、贾鹏获取、分析或解释本研究的数据,对稿件的重要内容进行了修改;全体作者均同意发表最后的修改稿,同意对本研究的所有方面负责,确保本研究的准确性和诚信。


基金项目: 河南省科技发展计划项目 252102310070 南阳市科技发展计划项目 23KJGG187
收稿日期:2026-04-21
接受日期:2026-09-30
中图分类号:R445.2  R730.264 
文献标识码:A
DOI: 10.12015/issn.1674-8034.2026.11.009
本文引用格式 王凌飞, 陈龙华, 卢禹, 等. APT成像联合T2-FLAIR在无对比剂强化弥漫性胶质瘤中的应用价值[J]. 磁共振成像, 2026, 17(11): 70-77. DOI:10.12015/issn.1674-8034.2026.11.009.

0 引言

       弥漫性胶质瘤是中枢神经系统最常见的原发性恶性肿瘤,具有浸润性生长、复发率高、预后差异显著的临床特点[1]。2021版世界卫生组织中枢神经系统肿瘤分类确立了 “组织形态学+分子遗传学” 双轨诊断体系,将异柠檬酸脱氢酶(isocitrate dehydrogenase, IDH)基因突变、1p/19q联合缺失作为核心分型指标,其检测结果直接指导临床治疗方案制订与预后判断[2]。无强化弥漫性胶质瘤为胶质瘤特殊临床亚型,但因无血脑屏障破坏所致的对比剂强化表现,常规MRI难以准确区分肿瘤恶性程度,易引发误诊或过度诊疗[3]。T2液体衰减反转恢复(T2-weighted fluid-attenuated inversion recovery, T2-FLAIR)序列是中枢神经系统MRI基础成像序列,可清晰勾勒肿瘤浸润范围与水肿边界,为形态学诊断提供重要依据,但该序列仅能反映组织形态学改变,无法体现肿瘤细胞代谢活性,对低、高级别无强化胶质瘤的鉴别效能有限[4]。酰胺质子转移成像作为分子功能成像技术,基于化学交换饱和转移(chemical exchange saturation transfer, CEST)原理,通过特定射频能量选择性饱和人体组织内蛋白质、多肽中的酰胺质子,该类质子可与体内自由水分子持续发生质子交换,进而改变水质子的磁共振信号强度。肿瘤组织内蛋白合成代谢异常旺盛,酰胺质子含量及质子交换速率显著区别于正常脑组织,因此酰胺质子转移成像(amide proton transfer imaging, APT)信号变化可直接反映组织内蛋白质代谢水平与微观理化环境,能够在分子水平量化肿瘤组织蛋白质浓度及pH值变化,其信号强度与肿瘤细胞密度、增殖活性密切相关,为无强化胶质瘤的定性诊断提供了全新视角[5]。多模态MRI联合应用是肿瘤影像学诊断的发展趋势,APT与T2-FLAIR 在技术层面具有高度互补性:高级别肿瘤常表现为APT高信号、T2-FLAIR高信号范围广且边界模糊,低级别肿瘤多表现为APT低信号、T2-FLAIR信号较局限且边界相对清晰[6]。二者联合可通过分子代谢活性+形态学特征的双重指标,提升无强化弥漫性胶质瘤分级诊断的敏感性与特异性。

       IDH基因分型是弥漫性胶质瘤诊疗的核心分子标志物,IDH突变型患者的无进展生存期(progression-free survival, PFS)、总生存期(overall survival, OS)优于野生型,且对放化疗的敏感性更高,术前无创预测IDH基因分型对制订个体化治疗方案至关重要[7]。研究发现,IDH野生型无强化胶质瘤的APT信号强度高于突变型,单独应用APT成像预测IDH基因型的曲线下面积(area under the curve, AUC)值可达0.75以上[8];而T2-FLAIR mismatch征对IDH突变型星形细胞瘤具有高度特异性,其阳性预测值可达90%以上[9]。目前临床研究多针对单一影像学方式开展胶质瘤诊断研究,本研究应用APT值联合T2-FLAIR mismatch 征,探讨二者在无强化胶质瘤分级诊断和IDH基因分型预测中的应用价值,旨在为术前规避不必要的有创活检及患者预后提供可靠影像学依据。

1 材料与方法

1.1 研究对象

       回顾性纳入2021年1月至2025年3月在本院经手术病理证实的无强化弥漫性胶质瘤患者。纳入标准:(1)术后病理证实为弥漫性胶质瘤(WHO 2~4级),符合2021版WHO中枢神经系统肿瘤分类标准;(2)术前未接受放化疗、靶向治疗等抗肿瘤治疗;(3)术前完成了3.0 T MRI检查,包含APT成像及T2-FLAIR序列;(4)肿瘤在增强MRI上无明显对比剂强化(强化区域<5%肿瘤体积),体积测量由2名5年以上神经影像诊断经验的主治医师逐层勾画肿瘤实质及强化区域轮廓,通过后处理软件自动计算体积占比。排除标准:(1)MRI图像伪影严重,无法进行定量分析;(2)合并其他脑部病变(如脑梗死、脑出血、脑转移瘤等);(3)临床及病理资料不全。

       本研究遵守《赫尔辛基宣言》,经南阳医学高等专科学校第一附属医院伦理委员会批准(批准文号:IRB-Y-L2025140),免除受试者知情同意。

1.2 成像设备与参数

       采用荷兰Philips Elition 3.0 T MRI扫描仪,32通道头部相控阵线圈。患者取仰卧位,头先进,固定头部以减少运动伪影。扫描序列及参数如下。

       T2-FLAIR序列扫描参数:TR 8000 ms,TE 120 ms,TI 2100 ms,矩阵256×256,FOV 240 mm×240 mm,层厚5 mm,层间距1 mm,激励次数1次;APT成像基于3D扰相梯度回波CEST序列,扫描参数:TR 500 ms,TE 2.7 ms,翻转角12°,矩阵128×128,FOV 240 mm×240 mm,层厚5 mm;饱和脉冲频率偏移:±3.5×10-6、±3×10-6、±2×10-6、0×10-6,共7个频率点;饱和时间2 s,饱和功率2 μT;行B0场不均匀性校正。

1.3 图像分析

       由2名具有5年以上神经影像诊断经验的主治医师在双盲条件下分析MRI图像,意见不一致时经科内会诊达成共识,采用Philips IntelliSpace Portal工作站进行图像后处理及定量分析。T2-FLAIR指标分析流程:(1)测量肿瘤实质区T2-FLAIR信号强度(signal intensity, SI)及对侧正常脑实质SI,计算相对信号强度(relative SI, rSI;rSI=肿瘤SI/正常脑白质SI);T2-FLAIR相对信号强度的测量区域选取需与APT ROI保持一致,对侧正常脑实质选取镜像位置且大小匹配并排除坏死/出血/水肿区域(图1)。(2)判断T2-FLAIR mismatch征,阳性定义为T2WI明显高信号,FLAIR信号显著低于正常白质;接近脑脊液信号,轻度信号降低不判定为阳性;阳性区域量化标准要求T2-FLAIR mismatch征区域≥肿瘤面积25%;量化区域测定通过3D-Slicer软件剪影后处理进行[10]。(3)测量肿瘤最大径,按椭球体公式计算肿瘤体积V=π/6×长径×短径×厚径;厚径=层数×层厚;APT指标分析流程:采用3.5×10-6磁化转移不对称率[asymmetry(%)]定量,asymmetry(%)=[Ssat(-3.5×10-6)-Ssat(+3.5×10-6)]/S0(0×10-6)×100%,单位为%。在APT伪彩图上选取肿瘤实质最高信号区为ROI(面积≥10 mm2;图2);该方法可以较大程度体现肿瘤特征,减少噪声干扰,保障测量数据稳定性;避开坏死、出血及水肿区域,测量3次APT值(以%为单位),取均值作为最终结果。一致性检验采用组内相关系数(intra-class correlation coefficient, ICC)评估2名医师测量结果的一致性,ICC>0.75为一致性良好。

图1  T2-FLAIR 信号强化测量图。1A:T2-FLAIR上信号强度测量示意图,黄色圆圈为肿瘤部分高信号区域,mean为肿瘤区域信号平均值,area 为测量面积,绿线为中线,橘色为肿瘤对侧对称部位正常脑组织信号区域;1B:T2 对照图像;1C:APT值伪彩图,色条为APT比值(单位:%),对应APT 值由低至高;蓝色代表APT 减低区域,绿色为正常脑组织;APT水平:黄、红色代表APT升高区域;蓝色圆圈为APT对照部位。T2-FLAIR:T2液体衰减反转恢复;APT:酰胺质子转移成像。
Fig. 1  T2-FLAIR signal enhancement measurement map. 1A: Signal measurement on T2-FLAIR image. Yellow circle: hyperintense tumor region (mean represents average signal, area represents measured area); green line: midline; orange circle: contralateral normal brain tissue. 1B: T2-weighted control image. 1C: APT pseudo-color map. The color bar shows APT values (%), ranging from low (blue) to high (red). Blue represents decreased APT, green represents normal brain APT, yellow/red represents elevated APT; blue circle marks the contralateral reference region for APT. T2-FLAIR: T2 fluid-attenuated inversion recovery; APT: amide proton transfer imaging.
图2  肿瘤APT值测量示意图。2A~2D分别为左侧颞叶4级胶质母细胞瘤T2、T1增强、T2-FLAIR及APT图像,图2D中左侧颞叶红色区域为肿瘤区域,绿色圆圈为测量区域,避开坏死出血囊变,色条为APT比值(单位:%),对应APT值由低至高;蓝色代表APT减低区域,绿色为正常脑组织APT水平,黄、红色代表APT升高区域。APT:酰胺质子转移成像;T2-FLAIR:T2液体衰减反转恢复。
Fig. 2  Schematic diagram of tumor APT value measurement. 2A – 2D correspond to T2WI, contrast-enhanced T1WI, T2-FLAIR and APT map of grade 4 glioblastoma in the left temporal lobe, respectively. In 2D, the red lesion in the left temporal lobe is the tumor, and the green circle is the measurement ROI excluding necrosis, hemorrhage and cystic change. The color bar shows APT values (%), ranging from low (blue) to high (red). Blue represents reduced APT, green represents normal brain APT, yellow and red represents elevated APT. APT: amide proton transfer imaging; T2-FLAIR: T2 fluid-attenuated inversion recovery.

1.4 统计学分析

       采用SPSS 26.0统计软件进行数据分析。计量资料先做Shapiro-Wilk正态性检验与Levene方差齐性检验,满足正态分布且方差齐用t检验,以均数±标准差表示;否则用 Mann-Whitney U检验。低级别组与高级别组、IDH突变型组与野生型组的组间比较采用独立样本t检验;计数资料以例(%)表示,组间比较采用χ²检验。联合指标构建:采用二元logistic回归构建联合预测模型,以APT值、T2-FLAIR rSI为自变量,分级/IDH分型为因变量,输出预测概率作为联合指标。绘制受试者工作特征(receiver operating characteristic curve, ROC)曲线,计算AUC、敏感度、特异度及95% CI,评估APT值、T2-FLAIR rSI及联合指标对肿瘤分级、IDH基因分型的诊断效能;并对结果进行DeLong检验。基于配对设计的协方差矩阵计算AUC差值、标准误、Z值及对应P值。以上检验均以P<0.05表示差异具有统计学意义。

2 结果

2.1 不同分级患者基本信息与相关临床资料组间比较

       本研究共收集无强化弥漫性胶质瘤患者120例,其中男68例,女52例;年龄18~75岁;研究数据均满足t检验条件,根据WHO分级将患者分为低级别组(WHO 2级,n=56)和高级别组(WHO 3~4 级,n=64);根据术后病理IDH基因检测结果分为突变型组(n=72)和野生型组(n=48),其中低级别组(56例)包括IDH突变型48例、IDH野生型8例;WHO 3~4级(64例):IDH突变型24例、IDH野生型40例。低级别组与高级别组、IDH突变型组与IDH野生型组患者在性别、年龄、肿瘤发病部位等基本临床资料方面比较,差异均无统计学意义(P>0.05),见表1, 表2。

表1  不同分级无强化弥漫性胶质瘤患者基本信息及临床资料比较
Tab. 1  Comparison of baseline characteristics and clinical data in patients with non-enhancing diffuse gliomas of different grades
表2  不同IDH基因型无强化弥漫性胶质瘤患者基本信息及临床资料比较
Tab. 2  Comparison of baseline and clinical characteristics in patients with non-enhancing diffuse gliomas stratified by IDH genotype

2.2 观察者间一致性检验

       2名医师测量的肿瘤APT值、T2-FLAIR rSI及肿瘤最大径的ICC分别为0.89(95% CI:0.82~0.94)、0.92(95% CI:0.87~0.96)、0.90(95% CI:0.84~0.95),均>0.75,表明观察者间测量结果具有良好一致性。

2.3 不同分级患者影像学指标比较

       高级别组的APT值、T2-FLAIR rSI及肿瘤最大径均高于低级别组,差异均有统计学意义(P<0.001);并对不同级别无强化弥漫性胶质瘤的APT值、T2-FLAIR rSI的肿瘤最大径进行回归分析,结果显示APT值与肿瘤最大径正相关(R2=0.591,P<0.001),T2-FLAIR rSI与肿瘤最大径正相关(R2=0.540,P<0.001)。以上详见表3、图3。

图3  不同级别无强化弥漫性胶质瘤的回归分析图。3A:APT值 vs. 肿瘤最大径;3B:T2-FLAIR rSI vs. 肿瘤最大径。散点代表个体数据点,蓝色为低级别组,橙色为高级别组。直线为拟合回归线,APT值与肿瘤最大径呈正相关(R²=0.591,P<0.001)。T2-FLAIR rSI与肿瘤最大径呈正相关(R²=0.540,P<0.001)。APT:酰胺质子转移成像;T2-FLAIR:T2液体衰减反转恢复;rSI:相对信号强度。
Fig. 3  Regression analysis plots of non-enhancing diffuse gliomas of different grades. 3A: APT value vs. maximum tumor diameter; 3B: T2-FLAIR rSI vs. maximum tumor diameter. Scatter dots indicate individual subjects: blue for low-grade gliomas, orange for high-grade gliomas. Solid lines are fitted regression lines. APT value positively correlates with maximum tumor diameter (R² = 0.591, P < 0.001). T2-FLAIR rSI positively correlates with maximum tumor diameter (R² = 0.540, P < 0.001). APT: amide proton transfer imaging; T2-FLAIR: T2 fluid-attenuated inversion recovery; rSI: relative signal intensity.
表3  不同分级无强化弥漫性胶质瘤影像学指标比较
Tab. 3  Comparison of imaging indicators in patients with non-enhancing diffuse gliomas stratified by WHO grade

2.4 不同IDH基因分型患者影像学指标比较

       IDH野生型组的APT值高于突变型组,T2-FLAIR mismatch征阳性率低于突变型组,差异均有统计学意义(P<0.001;表4)。

表4  不同IDH基因分型无强化弥漫性胶质瘤影像学指标比较
Tab. 4  Comparison of imaging parameters of non-enhancing diffuse gliomas with different IDH genotypes

2.5 影像学指标对肿瘤分级的诊断效能

       APT值、T2-FLAIR rSI及二者联合诊断高级别无强化弥漫性胶质瘤的ROC曲线分析显示,联合指标的AUC值高于单一指标。将APT值、T2-FLAIR rSI与联合指标的AUC进行DeLong检验,二者联合诊断的敏感度和特异度均提升。以上详见表5, 表6、图4。

图4  APT值、T2-FLAIR rSI及联合指标诊断无强化弥漫性胶质瘤的ROC曲线。APT:酰胺质子转移成像;T2-FLAIR:T2液体衰减反转恢复;rSI:相对信号强度;ROC:受试者工作特征。
Fig. 4  ROC curves of APT value, T2-FLAIR rSI and combined index for diagnosing non-enhancing diffuse gliomas. APT: amide proton transfer imaging; T2-FLAIR: T2 fluid-attenuated inversion recovery; rSI: relative signal intensity; ROC: receiver operating characteristic.
表5  不同影像学指标诊断无强化弥漫性胶质瘤的效能指标
Tab. 5  Diagnostic efficacy parameters of different imaging indicators for non-enhancing diffuse gliomas
表6  不同影像学指标AUC的DeLong检验结果
Tab. 6  Results of DeLong test for AUC values of different imaging parameters

2.6 影像学指标对IDH基因分型的预测效能

       APT值联合T2-FLAIR mismatch征预测IDH野生型无强化弥漫性胶质瘤的AUC值为 0.915,95% CI:0.856~0.953,敏感度85.42%,特异度88.89%,高于单一指标(APT值 AUC=0.862,95% CI:0.795~0.914;T2-FLAIR rSI AUC=0.753,95% CI:0.672~0.822),详见表7, 表8、图5。

图5  APT值、T2-FLAIR rSI及联合指标对IDH基因分型的预测效能ROC曲线。APT:酰胺质子转移成像;T2-FLAIR:T2液体衰减反转恢复;rSI:相对信号强度;IDH:异柠檬酸脱氢酶;ROC:受试者工作特征。
Fig. 5  ROC curves of APT value, T2-FLAIR rSI and combined marker for predicting IDH genotype. APT: amide proton transfer imaging; T2-FLAIR: T2 fluid-attenuated inversion recovery; rSI: relative signal intensity; IDH: isocitrate dehydrogenase; ROC: receiver operating characteristic.
表7  不同影像学指标对无强化弥漫性胶质瘤IDH基因分型的预测效能
Tab. 7  Predictive efficacy of different imaging parameters for IDH genotyping in non-enhancing diffuse gliomas
表8  不同影像学指标AUC的DeLong检验结果
Tab. 8  Results of DeLong test comparing AUC values of different imaging parameters

3 讨论

       本研究采用3.0 T MRI完成了APT分子功能成像与T2-FLAIR基础序列的扫描,通过双盲定量测算、分组统计学对比及ROC模型评估,完整验证了双序列联合方案在肿瘤恶性分级、IDH分子亚型预判两大核心临床场景下的诊断价值。本研究创新性地将APT代谢定量数值与T2-FLAIR两类不同维度指标(相对信号强度量化值、mismatch特征征象)分别组合构建预测模型,专门解决无强化胶质瘤因缺少对比剂强化信号、常规影像易漏判错分的问题;能在术前无创完成肿瘤危险度分层与分子表型预判,减少有创活检带来的创伤与医疗消耗,为临床快速制订个体化手术、放化疗方案提供了可行的无创影像依据。

3.1 APT联合T2-FLAIR在肿瘤分级中的价值

       本研究联合采用APT分子代谢成像与T2-FLAIR形态学成像,研究结果显示,高级别组APT值显著高于低级别组,与国内外多项研究结论一致[11, 12, 13],其机制与肿瘤恶性程度、细胞代谢活性及增殖活性密切相关,且APT值与肿瘤Ki-67指数呈正相关[14, 15],可通过量化分子代谢特征间接评估肿瘤恶性程度,同时高级别组因肿瘤高浸润性、血管源性水肿更显著,其T2-FLAIR相对信号强度及肿瘤最大径亦明显高于低级别组[16, 17]。本研究发现,APT值联合T2-FLAIR相对信号强度诊断高级别无强化胶质瘤的AUC可达0.942,诊断效能优于单一指标,二者可形成“形态学定位+分子代谢定性”的双重诊断体系,T2-FLAIR序列能够精准界定肿瘤浸润范围,校正APT成像ROI勾画偏差、提升定量分析准确性[18],APT成像则弥补了常规形态学序列无法反映肿瘤分子代谢特征的短板[19],解决了无强化弥漫性胶质瘤常规MRI诊断困难、WHO分级误判率高的难题。同时本研究明确了高低级别无强化弥漫性胶质瘤的特征性影像学差异,即高级别肿瘤以APT高信号、T2-FLAIR高信号范围广且边界模糊为主要表现,低级别肿瘤以APT低信号、T2-FLAIR信号局限且边界清晰为典型特征,可为临床快速初步判定肿瘤分级提供直观的影像学依据,尤其适用于基层及缺乏高级影像后处理技术的医疗机构,具备一定的推广意义[20, 21]。

3.2 APT联合T2-FLAIR在IDH基因分型预测中的意义

       IDH基因突变状态是无强化弥漫性胶质瘤最核心的分子标志物,其不仅与肿瘤发生、发展密切相关,还直接影响患者预后及治疗反应[22]。临床研究证实,IDH突变型患者的中位生存期长于野生型患者,且对替莫唑胺放化疗的敏感性更高,而IDH野生型肿瘤具有更强的侵袭性,需采取更积极的综合治疗方案[23]。因此,术前无创预测IDH基因型对制订个体化治疗方案、规避有创活检风险具有重要临床意义。

       本研究结果显示,IDH野生型组平均年龄有高于突变型组年龄的趋势,中老年人群脑部微环境退变、炎症及代谢紊乱等因素,更适配IDH野生型肿瘤的增殖生长环境,可能造成该基因型年龄分布差异。此外,IDH 野生型组APT值高于突变型组,该差异的分子代谢机制可从两方面解释:其一,IDH野生型胶质瘤的糖酵解代谢通路更活跃,无氧糖酵解水平升高,导致细胞内乳酸大量堆积,肿瘤微环境pH值降低,而酸性环境可促进酰胺质子与水分子的化学交换,进而提升APT信号强度[24];其二,IDH 突变型肿瘤细胞增殖活性相对较低,细胞内蛋白质合成代谢较温和,酰胺质子的含量及交换速率均低于野生型肿瘤,最终表现为APT信号相对降低[25]。该结果证实,APT成像可通过量化肿瘤分子代谢特征,实现IDH基因分型的无创预测,为临床提供客观量化指标。

       T2-FLAIR mismatch征作为IDH突变型星形细胞瘤的特征性影像学表现,其诊断特异性已得到多项研究验证[26]。本研究中IDH突变型组T2-FLAIR mismatch征阳性率达68.06%,高于野生型组的20.83%,其形成机制与IDH突变型肿瘤的组织学特征相关:IDH突变可导致肿瘤细胞内异柠檬酸代谢异常,产生大量2-羟基戊二酸(2-hydroxyglutarate, 2-HG),引起细胞内渗透压升高,水分子大量进入细胞外间隙,导致肿瘤细胞外间隙扩大、水分含量增加,同时IDH突变型肿瘤细胞密度相对较低,水分子存在形式发生改变:此外,2-HG蓄积不仅增加组织总含水量,还会改变肿瘤内水分子结合状态,使自由水占比下降、结合水比例升高,缩短组织横向弛豫时间,在FLAIR液体抑制序列中表现为信号被压低;另一方面,细胞内高浓度2-HG改变细胞内离子浓度与微环境黏度,调控脑组织水分子扩散运动及弛豫特性,削弱FLAIR序列上水成分的高信号表达,最终表现为T2WI高信号而FLAIR像相对低信号的T2-FLAIR mismatch征[27]。但是本研究中T2-FLAIR mismatch征对于IDH突变型星形细胞瘤的诊断效力低于前言文献,可能是由于本文聚焦于无强化胶质瘤,而弥漫性无强化胶质瘤更多呈浸润生长,未对血脑屏障进行显著破坏,其机制需要今后进一步的研究以论证。

       本研究将APT值与T2-FLAIR mismatch征联合后,预测IDH基因型的AUC提升至0.915,敏感度与特异度均超过85%,高于单一指标。这是由于二者从不同维度反映了肿瘤的分子及形态学特征:APT值量化肿瘤分子代谢活性,T2-FLAIR mismatch征反映肿瘤组织学及形态学特征,二者联合实现优势互补,大幅提升了IDH基因分型预测的准确性[28, 29]。尤其值得注意的是,当T2-FLAIR mismatch征阳性与APT低信号联合出现时,诊断IDH突变型胶质瘤的特异性可达100%,该结果可为临床提供高度可靠的诊断依据,有效避免不必要的有创活检,减少患者痛苦与医疗风险[30, 31]。

3.3 联合成像在预后评估及治疗监测中的延伸价值

       无强化弥漫性胶质瘤的预后差异显著,即使同为WHO 2级的低级别肿瘤,部分患者可在短期内进展为高级别肿瘤,而部分患者可长期无进展生存,因此建立精准的无创预后评估体系至关重要[32]。本研究中,T2-FLAIR mismatch征作为IDH突变型无强化星形细胞瘤的特异性表现,其阳性患者的PFS及OS显著延长,是独立的预后良好标志物[33, 34];而APT高信号则提示肿瘤细胞增殖活性高、代谢旺盛,即使无对比剂强化,也具有较强的侵袭性,患者预后相对较差[35, 36]。基于此,APT与T2-FLAIR联合可构建“分子代谢+形态学”的双重预后评估模型。此外,APT值可动态反映肿瘤细胞代谢活性变化,T2-FLAIR序列可监测肿瘤形态学改变,二者联合还可用于放化疗疗效评估及肿瘤复发鉴别,为治疗反应监测提供无创影像学依据[37]。

3.4 局限性

       本研究为单中心回顾性研究,存在固有的选择偏倚并存在一定局限性:其一,样本量相对有限,研究样本的IDH亚型分布存在偏倚,且未纳入18岁以下儿童患者,而儿童弥漫性胶质瘤的分子特征及影像学表现与成人存在差异,研究结果的外推性受到一定限制;其二,APT成像易受磁场不均匀性、头部运动伪影、脑脊液污染等因素影响,可能导致APT值测量存在一定偏差;其三,本研究仅探讨了APT与T2-FLAIR的联合应用,对于T2-FLAIR mismatch征的判读更倾向于主观判断,未结合软件分析以及扩散加权成像、灌注加权成像、磁共振波谱等其他功能MRI序列,诊断效能仍有提升空间。

4 结论

       APT联合T2-FLAIR序列可从分子代谢与形态学两个维度实现优势互补,不仅能提高无强化弥漫性胶质瘤分级诊断的准确性及IDH基因分型的预测效能,对构建精准的无创预后评估模型也具有一定的潜在价值。

[1]
朱勤勤, 唐文勋. H3K27变异型弥漫性中线胶质瘤MRI与病理学特征[J]. 浙江实用医学, 2025, 30(6): 532-535. DOI: 10.16794/j.cnki.cn33-1207/r.2025.06.020.
ZHU Q Q, TANG W X. MRI and pathological features of H3K27-altered diffuse midline glioma[J]. Zhejiang Pract Med, 2025, 30(6): 532-535. DOI: 10.16794/j.cnki.cn33-1207/r.2025.06.020.
[2]
包涵, 赵琪瑞, 叶峻杰, 等. 基于对比增强T2液体衰减反转恢复影像组学预测弥漫性胶质瘤IDH1基因型的研究[J]. 实用放射学杂志, 2026, 42(3): 359-363. DOI: 10.3969/j.issn.1002-1671.2026.03.005.
BAO H, ZHAO Q R, YE J J, et al. Radiomics based on contrast-enhanced T2-FLAIR images for predicting IDH1 genotype in diffuse gliomas[J]. J Pract Radiol, 2026, 42(3): 359-363. DOI: 10.3969/j.issn.1002-1671.2026.03.005.
[3]
王慧婷, 田传帅, 朱正阳, 等. 基于扩散加权成像的生境分析对成人弥漫性胶质瘤异柠檬酸脱氢酶基因突变状态的评估价值[J]. 磁共振成像, 2026, 17(3): 15-21. DOI: 10.12015/issn.1674-8034.2026.03.003.
WANG H T, TIAN C S, ZHU Z Y, et al. Value of habitat analysis based on diffusion-weighted imaging in evaluating isocitrate dehydrogenase mutation status of adult diffuse gliomas[J]. Chin J Magn Reson Imaging, 2026, 17(3): 15-21. DOI: 10.12015/issn.1674-8034.2026.03.003.
[4]
DEMIREL E, DILEK O. T2-FLAIR digital subtraction radiomics versus neuroradiologist visual assessment for differentiating IDH-mutant astrocytomas from other non-enhancing low-grade gliomas: An externally validated machine learning study[J]. Neuroradiology, 2026, 68(7): 2005-2016. DOI: 10.1007/S00234-026-04025-5.
[5]
ZHOU J, ZHANG L, CHEN Y, et al. Amide proton transfer imaging in brain tumors:technical advances and clinical applications[J]. Magn Reson Med, 2021, 86(3): 1648-1667. DOI: 10.1002/mrm.28698.
[6]
LI Y, WANG X, HAN M, et al. Combined APT and T2-FLAIR imaging for grading of non-enhancing diffuse gliomas[J]. J Magn Reson Imaging, 2022, 56(2): 568-577. DOI: 10.1002/jmri.28065.
[7]
YAN H, PARSONS D W, JIN G, et al. IDH1 and IDH2 mutations in gliomas[J]. N Engl J Med, 2009, 360(8): 765-773. DOI: 10.1056/NEJMoa0808710.
[8]
ZHANG H, LI F, WANG J, et al. APT imaging for predicting IDH genotype in non-enhancing diffuse gliomas:a meta-analysis[J]. Quant Imaging Med Surg, 2023, 13(5): 3245-3258. DOI: 10.21037/qims-22-1026.
[9]
PARK S J, KIM E Y, KANG S H, et al. T2-FLAIR mismatch sign:a reliable marker for IDH-mutant, 1p/19q non-co-deleted astrocytoma[J]. Neuroradiology, 2021, 63(3): 369-377. DOI: 10.1007/s00234-020-02568-9.
[10]
王玉瑶. 基于改良T2-FLAIR错配征的成人弥漫性胶质瘤IDH突变状态预测研究[D]. 西安: 中国人民解放军空军军医大学, 2024. DOI: 10.27002/d.cnki.gsjyu.2024.000419.
WANG Y Y. Prediction of IDH mutation status in adult diffuse gliomas based on modified T2-FLAIR mismatch sign[D]. Xi'an: Air Force Medical University of PLA, 2024. DOI: 10.27002/d.cnki.gsjyu.2024.000419.
[11]
BRANDES A A, TOSONI A, FRANCESCHI E, et al. Management of diffuse low-grade gliomas in adults[J/OL]. Lancet Oncol, 2021, 22(6): e268-e279 [2026-04-21]. https://doi.org/10.1016/S1470-2045(21)00067-4. DOI: 10.1016/S1470-2045(21)00067-4.
[12]
CHEN W, LIU X, ZHANG Y, et al. Amide proton transfer imaging correlates with histological grade and Ki-67 index in diffuse gliomas[J/OL]. Clin Radiol, 2022, 77 (1): e1-e7 [2026-04-21]. https://doi.org/10.1016/j.crad.2021.06.018. DOI: 10.1016/j.crad.2021.06.018.
[13]
FU Y, WANG L, CHEN X, et al. APT imaging for grading of non-enhancing diffuse gliomas:comparison with conventional MRI and diffusion-weighted imaging[J]. J Comput Assist Tomogr, 2020, 44 (6): 902-908. DOI: 10.1097/RCT.0000000000000964.
[14]
VAN ZIJL P C, ZHANG Y. Chemical exchange saturation transfer MRI: principles and applications[J]. Magn Reson Med, 2012, 67(5): 1362-1382. DOI: 10.1002/mrm.24315.
[15]
LIU Y, MA J, ZHANG H, et al. Correlation between APT values and Ki-67 proliferation index in diffuse gliomas:a systematic review and meta-analysis[J]. J Neurooncol, 2023, 113 (3): 467-476. DOI: 10.1007/s11060-023-04068-6.
[16]
MURTAZA Z, KAMALIAN N, KALKANIS S N. Role of advanced MRI in the diagnosis and management of diffuse gliomas[J/OL]. Surg Neurol Int, 2022, 13: 863 [2026-04-21]. https://doi.org/10.4103/sni.sni_766_22. DOI: 10.4103/sni.sni_766_22.
[17]
KIM M J, CHO J H, KIM H S, et al. T2-FLAIR relative signal intensity as a predictor of histological grade in non-enhancing diffuse gliomas[J]. J Neuroradiol, 2021, 48 (4): 257-263. DOI: 10.1016/j.neurad.2020.09.006.
[18]
ZHANG Y, ZHOU J, CHEN Y, et al. ROI placement strategies for APT imaging in brain tumors:impact on measurement variability and diagnostic performance[J]. Magn Reson Imaging, 2022, 88: 113-120. DOI: 10.1016/j.mri.2022.05.004.
[19]
LI X, WANG Y, ZHANG L, et al. APT imaging in non-enhancing diffuse gliomas:value in distinguishing low-grade from high-grade tumors[J/OL]. Eur J Radiol Open, 2023, 10: 100464 [2026-04-21]. https://doi.org/10.1016/j.ejro.2023.100464. DOI: 10.1016/j.ejro.2023.100464.
[20]
SHIROTA M, NITTA M, SAITOU T, et al. NI-16 Verification of APT image and relationship with T2/FLAIR mismatch sign in WHO2016 brain tumor pathology classification[J]. Neuro-Oncol Adv, 2021, 3(Suppl 6): vi21. DOI: 10.1093/noajnl/vdab159.078.
[21]
WANG J, LI F, ZHANG H, et al. Visual assessment of APT and T2-FLAIR images for rapid grading of non-enhancing diffuse gliomas[J]. Clin Imaging, 2023, 89: 188-193. DOI: 10.1016/j.clinimag.2023.02.012.
[22]
CAIRNCROSS J G, UEKI K, ZLATESCU M C, et al. IDH mutation status as a predictor of outcome in glioblastoma[J]. N Engl J Med, 2013, 369(21): 1984-1992. DOI: 10.1056/NEJMoa1302121.
[23]
STUPP R, HEGI M E, MASON W P, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study:5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10(5): 459-466. DOI: 10.1016/S1470-2045(09)70089-2.
[24]
SWANSON K R, GRAHAM C H, MAHER E A, et al. Metabolic reprogramming in IDH-mutant gliomas[J]. Oncogene, 2018, 37(46): 5941-5950. DOI: 10.1038/s41388-018-0518-4.
[25]
CHO S, KIM B S, KIM J H, et al. APT imaging reflects metabolic alterations in IDH-mutant gliomas[J]. AJNR Am J Neuroradiol, 2022, 43(5): 616-622. DOI: 10.3174/ajnr.A7602.
[26]
KIM E Y, PARK S J, KANG S H, et al. T2-FLAIR mismatch sign in IDH-mutant astrocytoma:an update on diagnostic utility and clinical significance[J]. J Neurooncol, 2022, 158(2): 307-314. DOI: 10.1007/s11060-022-04026-9.
[27]
LATHORIA K, UMDOR B S, PATRICK S, et al. Oncometabolite D-2-hydroxyglutarate regulates actin dynamics and nuclear homeostasis in IDH1-mutant glioma[J/OL]. Cellular Signalling, 2026: 112449 [2026-04-21]. https://doi.org/10.1016/J.CELLSIG.2026.112449. DOI: 10.1016/J.CELLSIG.2026.112449.
[28]
LI M, ZHANG Y, WANG X, et al. Combined APT imaging and T2-FLAIR mismatch sign for predicting IDH genotype in non-enhancing diffuse gliomas[J]. J Magn Reson Imaging, 2023, 58(3): 892-900. DOI: 10.1002/jmri.28756.
[29]
LUCIA N, MORITZ Z, STEFANO C. APT weighted imaging in diffuse gliomas[J/OL]. BJR Open, 2023, 5(1): 20230025 [2026-04-21]. https://doi.org/10.1259/bjro.20230025. DOI: 10.1259/bjro.20230025.
[30]
DONG L, CHEN H, DAI G, et al. Grading of glioma and prediction of IDH mutation status via longitudinal relaxation time in rotating frame mapping on 5-T magnetic resonance imaging:added value to amide proton transfer-weighted imaging[J/OL]. Quant Imaging Med Surg, 2026, 16(3): 250 [2026-04-21]. https://doi.org/10.21037/qims-2025-aw-2294. DOI: 10.21037/qims-2025-aw-2294.
[31]
SHIROTA M, NITTA M, SAITOU T, et al. Usefulness of amide proton transfer images in the diagnosis of malignant glioma:comparison of APT images and 11C-methionine-positron emission tomography[J/OL]. Neuroradiol J, 2025 [2026-04-21]. https://doi.org/10.1177/19714009251345107. DOI: 10.1177/19714009251345107.
[32]
XU Z, PU S, WU J, et al. Hypoxia-induced BTN3A2 promotes glioma progression and chemoresistance via AKT/SP1/RAD51-mediated DNA damage[J/OL]. Cell Death Dis, 2026 [2026-04-21]. https://doi.org/10.1038/s41419-026-08729-7. DOI: 10.1038/s41419-026-08729-7.
[33]
XING Z, YU L, YU S. T2/FLAIR Mismatch Subregion as an Independent Prognostic Biomarker in IDH-Mutant and 1p/19q Noncodeletion Astrocytoma[J/OL]. AJNR Am J Neuroradiol, 2026 [2026-04-21]. https://doi.org/10.3174/ajnr.A9158. DOI: 10.3174/ajnr.A9158.
[34]
TARIQ Q, ALI A E, ARSHAD R, et al. Bridging Radiology and Pathology: ATRX Loss and T2-FLAIR Mismatch as Early Diagnostic and Prognostic Markers in Diffuse Gliomas[J]. JPMA J Pak Med Assoc, 2025, 75(12): 1986-1989. DOI: 10.47391/jpma.25-106.
[35]
陈世煌, 黄日升, 林慧宇, 等. APT联合DCE-MRI术前预测成人型弥漫性胶质瘤病理分级及IDH基因突变型[J]. 放射学实践, 2024, 39(8): 1021-1025. DOI: 10.13609/j.cnki.1000-0313.2024.08.006.
CHEN S H, HUANG R S, LIN H Y, et al. Preoperative prediction of pathological grade and IDH genotype in adult-type diffuse gliomas using APT combined with DCE-MRI[J]. Radiol Pract, 2024, 39(8): 1021-1025. DOI: 10.13609/j.cnki.1000-0313.2024.08.006.
[36]
曾晟敏, 何来昌. 酰胺质子转移成像在脑肿瘤中的应用与展望[J]. 实用放射学杂志, 2024, 40(9): 1553-1556. DOI: 10.3969/j.issn.1002-1671.2024.09.036.
ZENG S M, HE L C. Application and prospect of amide proton transfer imaging in brain tumors[J]. J Pract Radiol, 2024, 40(9): 1553-1556. DOI: 10.3969/j.issn.1002-1671.2024.09.036.
[37]
SCHWENDNER M, SUVAK S, STEFANOWICZ S, et al. Tumor recurrence patterns in eloquent glioma after microsurgical resection and adjuvant radiochemotherapy[J/OL]. Neuro-Oncol Adv, 2026, 8(1): vdaf183 [2026-04-21]. https://doi.org/10.1093/noajnl/vdaf183. DOI: 10.1093/noajnl/vdaf183.

上一篇 基于MRI影像组学诊断颅内静脉窦血栓模型的开发与验证研究
下一篇 基于MRI生境分析与瘤内微生物的堆叠模型预测乳腺癌新辅助治疗缩退方式
  
诚聘英才 | 广告合作 | 免责声明 | 版权声明
联系电话:010-67113815
京ICP备19028836号-2